BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 21536859)

  • 1. ERG promotes T-acute lymphoblastic leukemia and is transcriptionally regulated in leukemic cells by a stem cell enhancer.
    Thoms JA; Birger Y; Foster S; Knezevic K; Kirschenbaum Y; Chandrakanthan V; Jonquieres G; Spensberger D; Wong JW; Oram SH; Kinston SJ; Groner Y; Lock R; MacKenzie KL; Göttgens B; Izraeli S; Pimanda JE
    Blood; 2011 Jun; 117(26):7079-89. PubMed ID: 21536859
    [TBL] [Abstract][Full Text] [Related]  

  • 2. LIM domain only-2 (LMO2) induces T-cell leukemia by two distinct pathways.
    Smith S; Tripathi R; Goodings C; Cleveland S; Mathias E; Hardaway JA; Elliott N; Yi Y; Chen X; Downing J; Mullighan C; Swing DA; Tessarollo L; Li L; Love P; Jenkins NA; Copeland NG; Thompson MA; Du Y; Davé UP
    PLoS One; 2014; 9(1):e85883. PubMed ID: 24465765
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TAL1 and LIM-only proteins synergistically induce retinaldehyde dehydrogenase 2 expression in T-cell acute lymphoblastic leukemia by acting as cofactors for GATA3.
    Ono Y; Fukuhara N; Yoshie O
    Mol Cell Biol; 1998 Dec; 18(12):6939-50. PubMed ID: 9819382
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aberrant TAL1 activation is mediated by an interchromosomal interaction in human T-cell acute lymphoblastic leukemia.
    Patel B; Kang Y; Cui K; Litt M; Riberio MS; Deng C; Salz T; Casada S; Fu X; Qiu Y; Zhao K; Huang S
    Leukemia; 2014 Feb; 28(2):349-61. PubMed ID: 23698277
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modeling T-cell acute lymphoblastic leukemia induced by the SCL and LMO1 oncogenes.
    Tremblay M; Tremblay CS; Herblot S; Aplan PD; Hébert J; Perreault C; Hoang T
    Genes Dev; 2010 Jun; 24(11):1093-105. PubMed ID: 20516195
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MicroRNA-193b-3p acts as a tumor suppressor by targeting the MYB oncogene in T-cell acute lymphoblastic leukemia.
    Mets E; Van der Meulen J; Van Peer G; Boice M; Mestdagh P; Van de Walle I; Lammens T; Goossens S; De Moerloose B; Benoit Y; Van Roy N; Clappier E; Poppe B; Vandesompele J; Wendel HG; Taghon T; Rondou P; Soulier J; Van Vlierberghe P; Speleman F
    Leukemia; 2015 Apr; 29(4):798-806. PubMed ID: 25231743
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MYCN is a novel oncogenic target in pediatric T-cell acute lymphoblastic leukemia.
    Astolfi A; Vendemini F; Urbini M; Melchionda F; Masetti R; Franzoni M; Libri V; Serravalle S; Togni M; Paone G; Montemurro L; Bressanin D; Chiarini F; Martelli AM; Tonelli R; Pession A
    Oncotarget; 2014 Jan; 5(1):120-30. PubMed ID: 24334727
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of quiescent thymic progenitors in TAL/LMO2-induced T-ALL chemotolerance.
    O'Connor KW; Kishimoto K; Kuzma IO; Wagner KP; Selway JS; Roderick JE; Karna KK; Gallagher KM; Hu K; Liu H; Li R; Brehm MA; Zhu LJ; Curtis DJ; Tremblay CS; Kelliher MA
    Leukemia; 2024 May; 38(5):951-962. PubMed ID: 38553571
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Establishing the transcriptional programme for blood: the SCL stem cell enhancer is regulated by a multiprotein complex containing Ets and GATA factors.
    Göttgens B; Nastos A; Kinston S; Piltz S; Delabesse EC; Stanley M; Sanchez MJ; Ciau-Uitz A; Patient R; Green AR
    EMBO J; 2002 Jun; 21(12):3039-50. PubMed ID: 12065417
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oncogenic cooperation between TCF7-SPI1 and NRAS(G12D) requires β-catenin activity to drive T-cell acute lymphoblastic leukemia.
    Van Thillo Q; De Bie J; Seneviratne JA; Demeyer S; Omari S; Balachandran A; Zhai V; Tam WL; Sweron B; Geerdens E; Gielen O; Provost S; Segers H; Boeckx N; Marshall GM; Cheung BB; Isobe K; Kato I; Takita J; Amos TG; Deveson IW; McCalmont H; Lock RB; Oxley EP; Garwood MM; Dickins RA; Uyttebroeck A; Carter DR; Cools J; de Bock CE
    Nat Commun; 2021 Jul; 12(1):4164. PubMed ID: 34230493
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activation of the
    Rahman S; Magnussen M; León TE; Farah N; Li Z; Abraham BJ; Alapi KZ; Mitchell RJ; Naughton T; Fielding AK; Pizzey A; Bustraan S; Allen C; Popa T; Pike-Overzet K; Garcia-Perez L; Gale RE; Linch DC; Staal FJT; Young RA; Look AT; Mansour MR
    Blood; 2017 Jun; 129(24):3221-3226. PubMed ID: 28270453
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A pentamer transcriptional complex including tal-1 and retinoblastoma protein downmodulates c-kit expression in normal erythroblasts.
    Vitelli L; Condorelli G; Lulli V; Hoang T; Luchetti L; Croce CM; Peschle C
    Mol Cell Biol; 2000 Jul; 20(14):5330-42. PubMed ID: 10866689
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disruption of a GATA2-TAL1-ERG regulatory circuit promotes erythroid transition in healthy and leukemic stem cells.
    Thoms JAI; Truong P; Subramanian S; Knezevic K; Harvey G; Huang Y; Seneviratne JA; Carter DR; Joshi S; Skhinas J; Chacon D; Shah A; de Jong I; Beck D; Göttgens B; Larsson J; Wong JWH; Zanini F; Pimanda JE
    Blood; 2021 Oct; 138(16):1441-1455. PubMed ID: 34075404
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dynamic interaction between TAL1 oncoprotein and LSD1 regulates TAL1 function in hematopoiesis and leukemogenesis.
    Li Y; Deng C; Hu X; Patel B; Fu X; Qiu Y; Brand M; Zhao K; Huang S
    Oncogene; 2012 Nov; 31(48):5007-18. PubMed ID: 22310283
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TAL1 hijacks MYCN enhancer that induces MYCN expression and dependence on mevalonate pathway in T-cell acute lymphoblastic leukemia.
    Tan SH; Tan TK; Yokomori R; Liao M; Huang XZ; Yeoh AEJ; Sanda T
    Leukemia; 2023 Oct; 37(10):1969-1981. PubMed ID: 37591943
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Suppression of super-enhancer-driven TAL1 expression by KLF4 in T-cell acute lymphoblastic leukemia.
    Noura M; Matsuo H; Yasuda T; Tsuzuki S; Kiyoi H; Hayakawa F
    Oncogene; 2024 Feb; 43(6):447-456. PubMed ID: 38102337
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overexpression of Lmo2 initiates T-lymphoblastic leukemia via impaired thymocyte competition.
    Abdulla HD; Alserihi R; Flensburg C; Abeysekera W; Luo MX; Gray DHD; Liu X; Smyth GK; Alexander WS; Majewski IJ; McCormack MP
    J Exp Med; 2023 Jun; 220(6):. PubMed ID: 36920307
    [TBL] [Abstract][Full Text] [Related]  

  • 18. JDP2: An oncogenic bZIP transcription factor in T cell acute lymphoblastic leukemia.
    Mansour MR; He S; Li Z; Lobbardi R; Abraham BJ; Hug C; Rahman S; Leon TE; Kuang YY; Zimmerman MW; Blonquist T; Gjini E; Gutierrez A; Tang Q; Garcia-Perez L; Pike-Overzet K; Anders L; Berezovskaya A; Zhou Y; Zon LI; Neuberg D; Fielding AK; Staal FJT; Langenau DM; Sanda T; Young RA; Look AT
    J Exp Med; 2018 Jul; 215(7):1929-1945. PubMed ID: 29941549
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oncogene regulation. An oncogenic super-enhancer formed through somatic mutation of a noncoding intergenic element.
    Mansour MR; Abraham BJ; Anders L; Berezovskaya A; Gutierrez A; Durbin AD; Etchin J; Lawton L; Sallan SE; Silverman LB; Loh ML; Hunger SP; Sanda T; Young RA; Look AT
    Science; 2014 Dec; 346(6215):1373-7. PubMed ID: 25394790
    [TBL] [Abstract][Full Text] [Related]  

  • 20. APOBEC signature mutation generates an oncogenic enhancer that drives LMO1 expression in T-ALL.
    Li Z; Abraham BJ; Berezovskaya A; Farah N; Liu Y; Leon T; Fielding A; Tan SH; Sanda T; Weintraub AS; Li B; Shen S; Zhang J; Mansour MR; Young RA; Look AT
    Leukemia; 2017 Oct; 31(10):2057-2064. PubMed ID: 28260788
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.